UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Annals of oncology, 2019-03, Vol.30 (3), p.447-455

2019

Volltextzugriff (PDF)

SP 134 Predictive and pharmacodynamic markers of susceptibility for targeting IGF-1R receptor

European journal of cancer (1990), 2011, Vol.47, p.S2-S2

Hirsch, F.R

2011

Volltextzugriff (PDF)

Consensus for HER2 alterations testing in non-small-cell lung cancer

ESMO open, 2022-02, Vol.7 (1), p.100395-100395, Article 100395

2022

Volltextzugriff (PDF)

I.17 ALK Genomic Aberrations in NSCLC and Clinical Implications

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1163-S1164

Hirsch, F.R.

2019

Volltextzugriff (PDF)

IBS15.02 Determinants of Response to ICI

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S106-S106

Hirsch, F.R.

2019

Volltextzugriff (PDF)

Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Annals of oncology, 2017-09, Vol.28, p.v460-v461

2017

Volltextzugriff (PDF)

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

European journal of cancer (1990), 2015-09, Vol.51, p.S602-S602

2015

Volltextzugriff (PDF)

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S37

2014

Volltextzugriff (PDF)

335 mTOR Inhibitor CC-223 Acts in Synergy with Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer Cell Lines

European journal of cancer (1990), 2012-11, Vol.48, p.102-103

2012

Volltextzugriff (PDF)

484 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients

European journal of cancer (1990), 2012-11, Vol.48, p.150-150

2012

Volltextzugriff (PDF)

Role of biomarkers for early detection of lung cancer and chemoprevention

The European respiratory journal, 2002-06, Vol.19 (6), p.1151-1158

2002

Volltextzugriff (PDF)

Targeted Therapy for Lung Cancer and Pancreatic Toxicity: Retrospective Study and Recommendations

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e10-e11

2024

Volltextzugriff (PDF)

OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

Annals of oncology, 2019-10, Vol.30, p.v51

2019

Volltextzugriff (PDF)

163P - OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

Annals of oncology, 2019-10, Vol.30, p.v51-v51

2019

Volltextzugriff (PDF)

Chemoprevention of lung cancer—from biology to clinical reality

Annals of oncology, 2004-02, Vol.15 (2), p.185-196

2004

Volltextzugriff (PDF)

P2.02-070 C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2125-S2126

2017

Volltextzugriff (PDF)

The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC

Oncogene, 2009-08, Vol.28 (31), p.S1

Hirsch, F.R

2009

Volltextzugriff (PDF)

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

Annals of oncology, 2016-08, Vol.27 (8), p.1573-1579

2016

Volltextzugriff (PDF)

EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S601

2022

Volltextzugriff (PDF)

EP.08F.01 Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S580-S581

2024

Volltextzugriff (PDF)

PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1606-S1606

2017

Volltextzugriff (PDF)

P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S236

2023

Volltextzugriff (PDF)

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

Annals of oncology, 2022-09, Vol.33, p.S1019-S1020

2022

Volltextzugriff (PDF)

P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S535-S536

2019

Volltextzugriff (PDF)

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines

Annals of oncology, 2008-06, Vol.19 (6), p.1053-1059

2008

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(104)
Reviews
(1)

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(21)
Oncology
(18)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Female
(13)
Male
(13)
Middle Aged
(12)
Adult
(11)
Pharmacology. Drug Treatments
(11)
Aged
(10)
Antineoplastic Agents
(10)
Lung Neoplasms - Drug Therapy
(10)
Pneumology
(10)
Tumors Of The Respiratory System And Mediastinum
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Lung Neoplasms - Pathology
(9)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Lung Neoplasms - Mortality
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

SP 134 Predictive and pharmacodynamic markers of susceptibility for targeting IGF-1R receptor

Consensus for HER2 alterations testing in non-small-cell lung cancer

I.17 ALK Genomic Aberrations in NSCLC and Clinical Implications

IBS15.02 Determinants of Response to ICI

Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

335 mTOR Inhibitor CC-223 Acts in Synergy with Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer Cell Lines

484 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients

Role of biomarkers for early detection of lung cancer and chemoprevention

Targeted Therapy for Lung Cancer and Pancreatic Toxicity: Retrospective Study and Recommendations

OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

163P - OX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

Chemoprevention of lung cancer—from biology to clinical reality

P2.02-070 C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer

The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC

EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed

EP.08F.01 Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples

P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

P1.12-05 Microenvironment Characterization of Small Cell Lung Cancer Xenografts Implanted in Hematopoietic Humanized Mice

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines

Suchergebnisse filtern